Unrecognized Respiratory Morbidity among Adolescents and Young Adults in Nigeria: Implications for Future Health Outcomes

Obianuju B. Ozoh1,2, Joy N. Eze3, Olufunke O. Adeyeye4, Ojebun Eromosele5, Sandra K. Dede6, Chizalu I. Ndukwu7, Richard Van Zyl-Smit8
1Department of Medicine, College of Medicine, University of Lagos, Lagos, Nigeria, 2Department of Medicine, Lagos University Teaching Hospital, Ibadan, Lagos, Nigeria, 3Department of Pediatrics, College of Medicine, University of Nigeria/University of Nigeria Teaching Hospital, Enugu, Nigeria, 4Department of Medicine, Lagos State University College of Medicine and the Lagos State University Teaching Hospital, Lagos, Nigeria, 5Department of Paediatrics, Nnamdi Azikiwe University, Awka, Anambra State, Nigeria, 6Department of Medicine, Division of Pulmonology, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa

Abstract

Background: Lung function impairment is a major determinant of morbidity and mortality. Unrecognized respiratory morbidity may be a missed opportunity to improve future health outcomes. Aim: The aim of this study was to investigate the prevalence of respiratory symptoms and spirometry abnormalities among medical students in Lagos, Nigeria. Methods: This was a cross-sectional study among students aged 16–35 years. We assessed frequency of respiratory symptoms, previous respiratory diagnosis, and spirometry abnormalities. The relationship between respiratory symptoms, spirometry pattern, and previous respiratory diagnosis was determined using the Chi-square test and stepwise forward logistic regression analysis. Results: Of 640 participants, 464 (72.5%) performed good quality spirometry tests. Two hundred and forty-four (52.6%) had at least one respiratory symptom. Preexisting conditions were only identified in 60 (12.9%): 49 (7.7%) asthma, 29 (4.5%) allergic rhinitis, 16 (2.5%) treated tuberculosis, and 8 (1.3%) bronchitis/chronic obstructive pulmonary disease. Using the Global Lung Function Initiative (GLI) lung function predicted values, obstructive (8.4%) and restrictive (25.4%) were common. An obstructive pattern was associated with previous diagnosis of asthma, but there was no significant association for the restrictive spirometry pattern. Conclusions: Among otherwise healthy students, respiratory symptoms and lung function abnormalities are common. The vast majority are without a formal diagnosis. Asthma accounted for the majority of obstructive spirometry pattern seen, but the restrictive abnormalities based on GLI equations remain unexplained. Further research is required to determine the cause of these abnormalities and long-term implications in apparently healthy young individuals.

Keywords: Adolescents, Nigeria, respiratory diagnosis, respiratory symptoms, spirometry abnormalities, young adult

Introduction

The burden of respiratory impairment among adolescents and young adults in low-middle-income settings of Africa has not been extensively evaluated. Impairment in lung function (reduced forced expiratory volume in 1 s [FEV1] and forced vital capacity [FVC]) is a major determinant of future multimorbidity including cardiopulmonary disease, metabolic disease, dementia, mild cognitive impairment, and all-cause mortality.1-5 Lung function in early adulthood also predisposes to future morbidity and mortality, and underrecognition at a young age may be a missed opportunity for early interventions to improve outcome.6

Lung volumes increase with age from infancy to early adulthood. The peak lung function reached provides the starting point for the age-related decline seen in adults. Consequently, lung function abnormalities in older adults may

Access this article online

Quick Response Code:  
Website: www.nigeriamedj.com  
DOI: 10.4103/nmj.NMJ_36_20

Address for correspondence: Dr. Joy N. Eze, Department of Pediatrics, College of Medicine, University of Nigeria/University of Nigeria Teaching Hospital, Ituku Ozalla, Enugu. E-mail: joy.eze@unn.edu.ng

Submitted: 20-Feb-2020 Revised: 08-May-2020 Accepted: 17-Jun-2020 Published: 04-Aug-2020

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com

How to cite this article: Ozoh OB, Eze JN, Adeyeye OO, Eromosele O, Dede SK, Ndukwu CI, et al. Unrecognized respiratory morbidity among adolescents and young adults in Nigeria: Implications for future health outcomes. Niger Med J 2020;61:210-7.
be the result of pathological accelerated lung function decline and/or failure to reach the expected peak volume during the first two decades of life. Reduced lung function in adolescents and young adults therefore may be as a result of suboptimal lung growth due to prenatal, early childhood, and adolescent life influences such as nutritional deficiencies, low birth weight, prematurity, exposure to air pollution, infections, low socioeconomic status, poverty, and genetic factors.\textsuperscript{7-10} Many of these risk factors are more prevalent in sub-Saharan Africa and may contribute to the increased burden of respiratory morbidity reported in this region.\textsuperscript{11}

Population-based studies in some regions of sub-Saharan Africa among older adults have demonstrated a high burden of respiratory symptoms and high prevalence of restrictive spirometry impairment (RSI).\textsuperscript{12-14} In adulthood, few interventions are able to improve lung function and earlier identification may provide an opportunity to intervene during active lung growth.

The aim of this study was to describe the burden of unrecognized respiratory morbidity among otherwise healthy adolescents and young adults attending a medical school in Lagos, Nigeria. Understanding the burden of respiratory morbidity in this age group will provide important insight into unrecognized respiratory disease in young people and serve as an opportunity to inform policy to improve the respiratory health of adolescents and young adults in a developing country.

**METHODS**

We conducted a cross-sectional survey among adolescents and young adults attending a College of Medicine. All 1822 students of the College of Medicine were eligible and invited to participate. This comprised students in the faculties of clinical sciences, dental sciences, and basic medical sciences. We included consenting students 16–35 years old and excluded those with specific contraindications to spirometry such as recent surgery, active respiratory infection including tuberculosis, pregnancy, or an uncontrolled medical condition.

**Questionnaire administration**

The participants self-completed a questionnaire to obtain sociodemographic data and information on respiratory symptoms and previous respiratory diagnosis. We used the Modified Medical Research Council (MMRC) questionnaire on respiratory symptoms to assess respiratory symptoms, and a previous physician diagnosed respiratory conditions of interest (asthma, chronic bronchitis/chronic obstructive pulmonary disease (COPD), hay fever, and previous tuberculosis). The MMRC questionnaire on respiratory symptoms is a 17-item questionnaire that assesses respiratory symptoms (cough, phlegm, breathlessness, and wheeze) and smoking history (ever smoker was defined as having smoked at least one stick of cigarette daily for 1 year or up to 100 sticks of cigarette in the lifetime). It reliably relates symptoms and lung function and has been used to study respiratory epidemiology for several decades.\textsuperscript{15} The questionnaire did not require translation as all university students in Nigeria are fluent in English.

We categorized the symptoms on the MRC questionnaire into:

- **Moderate:** Recurrent, morning, daytime, or night cough (with increased severity if it occurred on most days for as long as 3 months each year)
- **Phlegm:** Recurrent, morning, daytime, or nighttime sputum production during cold weather (with increased severity if it occurred on most days for as long as 3 months each year)
- **Any respiratory symptom:** The presence of any of the above respiratory symptoms.

We also categorized those with any previous diagnosis of asthma, bronchitis/COPD, allergic rhinitis or tuberculosis as “any respiratory diagnosis” and measured oxygen saturation (SPO\textsubscript{2}) using the Econet\textsuperscript{®} pulse oximeter from the middle finger, after 1 min of recording.

**Spirometry testing**

The Vitalograph\textsuperscript{®} Spirotrac V Pneumotrac spirometer was used to perform spirometry according to the American Thoracic Society/European Respiratory Society (ATS/ERS) standards for measurement of spirometry.\textsuperscript{16} All test results were individually checked and independently verified for quality. Acceptable prebronchodilator tests were included for analysis and the FEV\textsubscript{1}, FVC, and FEV\textsubscript{1}/FVC ratio categorized into the following ventilatory patterns:

- Obstructive impairment: FEV\textsubscript{1}/FVC <the lower limit of normal (LLN) with FVC ≥LLN
- RSI: FVC <LLN with FEV\textsubscript{1}/FVC ≥LLN
- Mixed (obstructive and restrictive): FEV\textsubscript{1}/FVC <LLN with FVC <LLN
- Normal: FEV\textsubscript{1}/FVC ≥LLN with FVC ≥LLN.

The presence of any of the abnormal patterns was considered as “abnormal spirometry.”

We utilized the Global Lung Function Initiative (GLI) reference equation for “others” to determine spirometry pattern\textsuperscript{17} and categorized the severity of impairment for the FEV\textsubscript{1} and FVC, respectively, using the z-scores as proposed by Quanjer et al.\textsuperscript{18} as follows:

- **Mild:** z-score ≥−2
- **Moderate:** −2.5 less than or equal z-score <−2
- **Moderately severe:** −3 less than or equal z-score <−2.5
• Severe: −4 less than or equal z-score <−3
• Very severe: z-score <−4.

To further evaluate the presence of lung function abnormalities and the impact of choice of reference equation on the frequency, the ERS/Polgar reference equation with 13% correction for Africans and the newly developed local reference equation from a Nigerian population, respectively, were also applied.

Data analysis
We described characteristics of the population using data for all students who completed the questionnaire but only included the data for those with adequate spirometry tests for the description of ventilatory function and other analyses. A comparison of the frequency of respiratory symptoms and previous respiratory diagnosis among those with adequate spirometry and those without was performed using the Chi-square test and Student’s t-test.

We used descriptive statistics to report the participant characteristics and explored the relationship between respiratory symptoms, spirometry pattern, and previous respiratory diagnosis, respectively, using the Chi-square test. Independent determinants of respiratory symptoms and abnormal spirometry pattern were assessed using stepwise forward logistic regression analysis. For the multiple regression models, we included only variables with \( P < 0.02 \) in bivariate analysis. Age and sex were included as prior variables in the model for the spirometry patterns. A two-sided \( P < 0.05 \) was considered significant for all associations.

We obtained ethical approval from the Health Research Ethics Committee of the Lagos University Teaching Hospital (approval number: ADM/DCST/HREC/APP/2162; dated June 27, 2016) and written informed consent from each participant.

Results
A total of 640 of the 1822 eligible students participated in the study, giving a participation rate of 35.1%. Of the students that participated, 464/640 (72.5%) performed good quality spirometry tests. The age of participants ranged from 16 years to 35 years and 2.7% were current tobacco smokers. All participants had normal \( \text{SPO}_2 \) (≥ 95%) and 74% had normal body mass index (BMI) (18.5–24.9 kg/m\(^2\)). Participants with good quality spirometry had higher mean \( \text{SPO}_2 \) compared to those with poor quality spirometry [Table 1].

Respiratory symptoms
Two hundred and forty-four (52.6%) had “any respiratory symptom.” The frequencies of reported symptoms (in descending order of frequency) were as follows: “trigger-related symptoms” 159 (24.8%), “exercise-induced symptoms” 158 (24.7%), “SOB” 124 (24.1%), “cough” 118 (18.4%), “phlegm” 106 (16.6%), and “sleep-related symptoms” 90 (14.1%), respectively.

Thirty-four (5.3%) experienced cough and 50 (7.8%) wheeze on moderate exercise such as climbing stairs, 13 (2.0%) had a combination of cough, wheeze, and chest tightness, 57 (8.9%) had sleep broken by difficulty in breathing, and 140 (21.9%) experienced wheeze on exposure to dust. Eleven (1.7%) were incapacitated by SOB and had to stop when walking at own pace on level ground. One hundred and eight (16.9%) reported cough and 86 (13.4%) reported phlegm during the day or night.

---

| Characteristic          | All participants (\( n=640 \)) | Participants with good quality spirometry (\( n=464 \)) | Participants without good quality spirometry (\( n=176 \)) | \( P \) |
|-------------------------|---------------------------------|----------------------------------------------------------|----------------------------------------------------------|------|
| Mean age±SD             | 21.7±2.9                        | 21.5±3.0                                                 | 22.0±2.4                                                 | 0.04*|
| Age group               |                                 |                                                          |                                                          |      |
| 16-19                   | 132 (20.6)                      | 114 (24.6)                                               | 18 (10.2)                                                | <0.001*|
| 20-24                   | 428 (66.9)                      | 289 (62.3)                                               | 139 (79.0)                                               |      |
| 25-29                   | 66 (10.3)                       | 49 (10.6)                                                | 17 (9.7)                                                 |      |
| 30-35                   | 14 (2.2)                        | 12 (2.6)                                                 | 2 (1.1)                                                  |      |
| Sex                     |                                 |                                                          |                                                          |      |
| Female                  | 338 (52.8)                      | 246 (53.0)                                               | 92 (52.3)                                                | 0.87 |
| Male                    | 302 (47.2)                      | 218 (47.0)                                               | 84 (47.7)                                                |      |
| Height                  | 1.69±0.08                       | 1.70±0.08                                                | 1.69±0.09                                                | 0.67 |
| BMI in kg/m\(^2\)       |                                 |                                                          |                                                          |      |
| Underweight (<18.5)     | 36 (5.6)                        | 23 (5.0)                                                 | 13 (7.4)                                                 | 0.36 |
| Normal (≥18.5 and <25)  | 473 (74.0)                      | 339 (73.2)                                               | 134 (76.1)                                               |      |
| Overweight (25-29.9)    | 102 (16.0)                      | 81 (17.5)                                                | 21 (11.9)                                                |      |
| Obesity class 1 (30-35) | 23 (3.6)                        | 17 (3.7)                                                 | 6 (3.4)                                                  |      |
| Obesity class 2 (>35)   | 5 (0.8)                         | 3 (0.6)                                                  | 2 (1.1)                                                  |      |
| \( \text{SPO}_2 \)      | 98.0±0.7                        | 98.0±0.7                                                 | 97.8±0.8                                                 | 0.003*|
| Years of schooling      | 15.4±2.2                        | 15.4±2.3                                                 | 15.3±2.0                                                 | 0.74 |
| Current tobacco smoking | 17 (2.7)                        | 14 (3.0)                                                 | 3 (1.7)                                                  | 0.36 |

\(^{*}\)One female missing among participants with good quality spirometry, \( P \) value for comparison between those with good quality spirometry and those without, \(^{*}\)Significant difference. \( \text{SPO}_2 \) – Oxygen saturation; SD – Standard deviation
in cold weather. Twenty-two (3.4%) and 34 (5.3%) had cough and phlegm respectively that lasted up to 3 months/year. There was no difference in the frequency of respiratory symptoms between those with good quality spirometry and those with poor quality spirometry \( (P = 0.59; \text{Supplementary Table 1}) \), suggesting that inability to perform spirometry was likely due to technical errors.

Figure 1 and Supplementary Table 2 show the frequency of respiratory symptoms across age groups among participants with good quality spirometry for males and females, respectively. Previous respiratory diagnosis Preexisting respiratory conditions were diagnosed in 60 (12.9%) of the participants: 49 (7.7%) had a history of asthma, 29 (4.5%) allergic rhinitis, 16 (2.5%) treated tuberculosis, and 8 (1.3%) bronchitis/COPD. The frequency of respiratory diagnosis did not also differ between those with good quality spirometry and those with poor quality spirometry (data not shown).

### Spirometry pattern and severity of impairment

For participants with acceptable spirometry, the frequency of obstructive impairment was 8.4% (10.6% in females and 6.0% in males). Table 2: Frequency of abnormal spirometry pattern among participants by age group and body mass index categories

| Variable | Obstructive impairment (%) | Restrictive spirometry impairment (%) | Mixed spirometry impairment (%) |
|----------|-----------------------------|--------------------------------------|---------------------------------|
|          | GLI equation Male | ERS/Polgar Male | Local equation Male | GLI equation Male | ERS/Polgar Male | Local equation Male | GLI equation Male | ERS/Polgar Male | Local equation Male |
| Age      | 16-19          | 8(11.4) | 4 (9.1) | 3 (4.3) | 1 (2.3) | 1 (1.4) | 4 (9.1) | 19 (27.1) | 16 (36.4) | 9 (12.9) | 6 (13.6) | 6 (8.6) | 3 (6.8) |
|          | 20-24          | 18 (11.5) | 8 (6.0) | 4 (2.6) | 4 (3.0) | 7 (4.5) | 12 (9.0) | 34 (20.5) | 36 (27.1) | 9 (5.8) | 4 (3.0) | 1 (0.6) | 1 (0.8) |
|          | 25-29          | -      | 1 (7.7) | -      | 2 (6.3) | -      | 3 (9.4) | 7 (41.2) | 7 (21.9) | 3 (17.6) | -      | -      | -      |
|          | 30-35          | -      | -      | -      | -      | -      | -      | 1 (11.1) | -      | -      | -      | -      | -      |
| BMI*     | <18.5          | -      | 1 (16.7) | -      | -      | -      | 1 (16.7) | 3 (50.0) | 3 (17.6) | 2 (33.3) | -      | 1 (16.7) |
|          | 18.5-24.9      | 14 (8.3) | 9 (5.2) | 4 (2.4) | 3 (1.7) | 6 (3.6) | 13 (7.5) | 6 (35.3) | 52 (29.9) | 16 (9.5) | 8 (4.6) | 3 (1.8) | 3 (1.7) |
|          | 25-29.9        | 9 (19.1) | 3 (10.0) | 3 (6.4) | 4 (13.3) | 5 (16.7) | 47 (27.8) | 4 (13.3) | 1 (2.1) | -      | 4 (8.5) | -      | -      |
|          | 30-34.9        | 2 (22.2) | -      | -      | 1 (11.1) | -      | 4 (8.5) | 1 (12.5) | 1 (11.1) | -      | -      | -      | -      |

*One female participant with missing BMI has obstructive pattern on the GLI and local equations, respectively, and normal pattern on the ERS/Polgar. BMI – Body mass index; ERS – European Respiratory Society; GLI – Global Lung Function Initiative
6.0% in males), using the GLI equation. If the ERS/Polgar equations were applied, the prevalence was 3.0% (2.8% in females and 3.2% in males), and using the local equation, it was 5.8% (3.3% in females and 7.7% in males). The frequency of RSI was 25.4% (23.6% in females and 27.5% in males) using the GLI equation, 6.7% (8.5% in females and 4.6% in males) using the ERS/Polgar, and 2.4% (2.8% in females and 1.8% in males) using local equation, respectively. There was a statistically significant difference in the distribution of spirometry pattern between the GLI equation and the ERS/ Polgar equation, between the GLI equation and the local equation, and between the ERS/Polgar equation and the local equation, respectively ($P < 0.001$ in all instances). Table 2 shows the frequency of abnormal spirometry pattern among participants by age group and BMI categories.

Based on the FEV1 z-score, 13 (2.8%), 52 (11.2%), 15 (3.2%), and 13 (2.8%) of all 464 participants had mild, moderate, moderately severe, and severe impairment, respectively.

When based on the FVC z-score, 15 (3.2%), 46 (9.9%), 17, (3.7%), 6 (1.3%), and 2 (0.4%) had mild, moderate, moderately severe, severe, and very severe impairment, respectively.

**Relationship between abnormal spirometry, respiratory symptoms, and previous respiratory diagnosis**

The mixed spirometry pattern was merged into the RSI and the obstructive impairment, respectively, due to the limited number of persons with mixed impairment. There was no significant association between “abnormal spirometry” and “any respiratory symptom” ($P = 0.60$) nor between “abnormal spirometry” and “any respiratory diagnosis” ($P = 0.09$). There was a significant association between “any respiratory diagnosis” and “any respiratory symptom” ($P < 0.001$).

Females with sleep-related symptoms had a significantly higher proportion of obstructive pattern compared to the proportion with RSI and normal patterns, respectively ($P = 0.02$). Figure 2 and Table 3 show the relationships between respiratory symptoms, respiratory diagnosis, and abnormal spirometry, respectively. There was a significant association between obstructive pattern compared to RSI or normal pattern among those with a diagnosis of asthma in both females and males ($P = 0.02$ for females and $P = 0.03$ for males).

**Factors associated with restrictive and obstructive spirometry impairment**

The factors associated with restrictive and obstructive spirometry impairment based on the GLI equation were evaluated. Age, sex, BMI, or smoking status was not associated with either restrictive or obstructive impairment in both bivariate and multivariate analyses.

**Discussion**

We found a high burden of respiratory symptoms and low rates of respiratory diagnosis in a “healthy” student population. Over half of the students reported at least one chronic respiratory symptom, and only 5.6% with both respiratory symptoms and abnormal spirometry had a respiratory diagnosis. The frequency of abnormal spirometry pattern was high, mostly RSI, but also a substantial burden of obstructive impairment. While the obstructive impairment was recognized by a previous diagnosis of asthma and “sleep-related symptoms,” respectively, the RSI has no significant associations and therefore was mostly unrecognized.

This study evaluating respiratory symptoms, abnormal spirometry, and previous respiratory diagnosis among medical students is unique in many ways. First, we assessed the burden of disease in a young and potentially privileged group (likely of the middle-upper socioeconomic class) with relatively good access to health-care services. Second, we explored the relationship between respiratory morbidity and respiratory diagnosis to assess gaps and unmet needs in respiratory care delivery for this age group, and third, we used different reference equations to determine spirometry patterns.

The use of three reference equations in this study clearly demonstrates the disparity in the burden of respiratory morbidity based on choice of reference equation. There was a significant
disparity in the burden of spirometry impairment that was more profound for the RSI when any of the three equations was used. This has clinical and epidemiological consequences that make it expedient to use the most appropriate equation under the right circumstance.

For epidemiological studies, an equation with the most robust and updated statistical method that is generalizable across diverse populations is recommended as it enables comparison across studies and augurs well for public health intervention.

The GLI equation meets these criteria and demonstrates the highest frequency of respiratory impairment, although this could be overdiagnosing disease based on lung function. However, the proportion with moderate-to-severe impairment (approximately 15% based on either the FEV1 or FVC) raises some concern. The ERS/Polgar equation has limitations regarding the preexisting health of the adult participants used in the development of the equation and approximation of values for females. The local reference equation used simple linear regression models, which may not be robust for the statistical analysis and has a narrow age range. Although locally derived reference equations may appear to be a pragmatic choice particularly in the clinical setting, previous reports suggest that they may not be the most appropriate for epidemiological purposes. Shared exposures such as social and environmental factors that impair lung function in the general population may limit the benchmark for normality with adverse health outcomes. The worldwide Burden of Obstructive Lung Disease study which demonstrated that lower FVC was positively associated with country of origin, lower gross national income, and mortality alludes to this. Therefore, for epidemiological studies, the use of an equation with the highest benchmark for defining normality such as the GLI may be advocated because it

| Table 3: Relationship between abnormal spirometry pattern, respiratory symptoms, and respiratory diagnosis |
|------------------------------------------------------------------------------------------------|
| **Variable** | **Females** | | | | **Males** | | | |
| | **RSI (n=60), n (%)** | **Obstructive (n=26), n (%)** | **P** | | **RSI (n=67), n (%)** | **Obstructive (n=13), n (%)** | **P** |
| Respiratory symptoms | | | | | | | |
| SOB | 19 (31.7) | 8 (30.8) | 0.89 | | 9 (13.4) | 2 (15.4) | 0.90 |
| Exercise-induced symptoms | 21 (35.0) | 11 (42.3) | 0.79 | | 14 (20.9) | 2 (15.4) | 0.43 |
| Sleep-related symptom | 6 (10.0) | 9 (34.6) | 0.02 | | 9 (13.4) | 1 (7.7) | 0.83 |
| Trigger-related symptom | 22 (36.7) | 7 (26.9) | 0.08 | | 19 (28.4) | 4 (30.8) | 0.24 |
| Cough | 13 (21.7) | 8 (30.8) | 0.62 | | 7 (10.4) | 1 (7.7) | 0.83 |
| Phlegm | 9 (15.0) | 6 (23.1) | 0.66 | | 12 (17.9) | 2 (15.4) | 0.58 |
| Any respiratory symptom | 37 (61.7) | 18 (69.2) | 0.76 | | 30 (44.8) | 5 (38.5) | 0.78 |
| Previous diagnosis | | | | | | | |
| Ever had asthma | 3 (5.0) | 5 (19.2) | 0.02 | | 8 (11.9) | 4 (30.8) | 0.03 |
| Ever had bronchitis/COPD | - | 1 (3.8) | 0.33 | | 3 (4.5) | - | - |
| Ever had allergic rhinitis | 3 (5.0) | 1 (3.8) | 3 (4.5) | 1 (7.7) | 0.10 |
| Previous tuberculosis treatment | 3 (5.0) | - | 1.19 | | - | - | 0.31 |

SOB – Shortness of breath; COPD – Chronic obstructive pulmonary disease; RSI – Respiratory spirometry impairment

| Table 4: Multivariate regression analysis for determinants of respiratory symptoms |
|---------------------------------------------------------------|
| **Variable** | **Any SOB** | **Exercise induced** | **Sleep related** | **Trigger related** | **Cough** | **Sputum production** | **Any respiratory symptom** |
| Age group | **OR (95% CI)** | **OR (95% CI)** | **OR (95% CI)** | **OR (95% CI)** | **OR (95% CI)** | **OR (95% CI)** | **OR (95% CI)** |
| 16-19 | 3.83 (0.46-31.58) | 3.96 (0.47-33.75) | - | - | - | - | 4.02 (1.01-16.02) |
| 20-24 | 2.48 (0.31-20.05) | 3.42 (0.41-28.41) | - | - | - | - | 2.53 (0.66-9.74) |
| 25-29 | 2.96 (0.34-26.13) | 3.46 (0.38-31.46) | - | - | - | - | 2.32 (0.55-9.81) |
| 30-35 | Reference | Reference | - | - | - | - | - |
| Female sex | 2.71 (1.71-4.30) | 2.82 (1.79-2.47) | - | 1.82 (1.12-2.95) | - | 2.25 (1.54-3.29) |
| BMI | | | | | | | |
| Underweight | - | 0.17 (0.01-2.29) | - | - | - | - | - |
| Normal weight | - | 0.25 (0.02-2.77) | - | - | - | - | - |
| Overweight | - | 0.42 (0.04-4.87) | - | - | - | - | - |
| Obesity class 1 | - | 0.40 (0.02-5.57) | - | - | - | - | - |
| Obesity class 2 | - | Reference | - | - | - | - | - |

BMI – Body mass index; SOB – Shortness of breath, OR – Odds ratio; CI – Confidence interval

Ozoh, et al.: Respiratory morbidity among adolescents and young adults in Nigeria
facilitates early detection of impairments and guides public health interventions.

The high burden of RSI in this present study is consistent but higher than in previous population-based studies in Nigeria and Malawi among older adults. This trend may indicate a survival benefit among those with higher lung function and warrants further evaluation. At variance with previous studies, we did not find a significant association between spirometry impairment and age, sex, BMI, or tobacco smoking, respectively, which may be related to the younger age, relatively uniform socioeconomic status, and normal BMI among our participants. The frequency of tobacco smoking in our study was low, consistent with previous reports in this university, and may have had minimal effect. The consequences of these social and environmental factors on lung growth are important areas for future longitudinal research in Africa.

The rate of diagnosed asthma among these students (7.2%) is much higher than in the general population in Lagos (2.3%). Schooling on a university hospital campus infers good access to high-quality medical care which is likely to promote health-seeking behavior and disease diagnosis among this group compared to the general population. Furthermore, most participants with obstructive impairment had a previous physician diagnosis of asthma, suggesting substantial clinical recognition of obstructive impairment that provides opportunity for treatment. In contrast, the RSI is surreptitious, usually clinically unrecognized and untreated boding for future adverse health outcomes. It is, therefore, reasonable to make a public health priority the implementation of measures such as improvement in social and environmental factors for the primordial prevention of suboptimal lung growth to reduce RSI. Routine screening for early detection may also be a cost-effective approach as it may provide opportunity for early treatment. For example, leveraging on the already compulsory premiership health screening for university students may be an opportunity for implementing routine spirometry testing among university students.

The strengths in this study include the rigorous spirometry quality assurance process taken to provide reliable data from a group of young persons from sub-Saharan Africa. The use of three reference equations is an additional strength as it highlights the disparity in burden of disease based on choice of reference equation. Evaluation of the relationship between spirometry impairment, respiratory symptoms, and previous respiratory diagnosis allowed us to recognize potential gaps in respiratory care delivery among these students with relatively good access to health care, which may not be true for the general population.

We acknowledge the voluntary participation of students in this study as a potential limitation because those concerned about suboptimal respiratory health may have chosen to participate. The limited generalizability of our finding to the general population of adolescents and young adults in Nigeria is also recognized. However, information on respiratory health among persons of relatively higher socioeconomic status in Africa is currently lacking, and our findings may be a glimpse of the best-case scenario in our region. Furthermore, self-reported respiratory diagnosis was unverified and the study was not powered to identify risks for spirometry impairment or respiratory symptoms. Therefore, the associations we have reported are only exploratory.

**Conclusions**

We found a high burden of respiratory symptoms and unrecognized RSI in this “healthy” population of young adults. There was a wide disparity in the burden of spirometry impairment based on choice of reference equation. The three evaluated lung function equations raise significant issues regarding the best choice for abnormality identification (epidemiologically) but not necessarily disease for treatment (clinically). This calls for further research to clearly elucidate and mitigate against recognized risk factors for suboptimal lung growth and to prospectively conceptualize and evaluate potential interventions to improve outcome.

**Acknowledgment**

We wish to thank the students of the College of Medicine, University of Lagos, who participated in this study.

**Financial support and sponsorship**

The study received part funding from Dr. Obianuju Ozoh’s ATS MECOR grant 2015.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Duong M, Islam S, Rangarajan S, Leong D, Kurmi O, Teo K, *et al.* Mortality and cardiovascular and respiratory morbidity in individuals with impaired FEV1 (PURE): An international, community-based cohort study. Lancet Glob Health 2019;7:e613-23. Available from: https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(19)30070-1/fulltext. [Last accessed on 2019 Jul 26].

2. Magnussen C, Ojeda FM, Raye A, Zeller T, Sinning CR, Pfeiffer N, *et al.* FEV1 and FVC predict all-cause mortality independent of cardiac function – Results from the population-based Gutenberg Health Study. Int J Cardiol 2017;234:64-8.

3. Lutsey PL, Chen N, Mirabelli MC, Lakshminarayan K, Knopman DS, Vosel KA, *et al.* Impaired lung function, lung disease, and risk of incident dementia. Am J Respir Crit Care Med 2019;199:1385-96.

4. Pathan SS, Gottesman RF, Mosley TH, Knopman DS, Sharrett AR, Alonso A. Association of lung function with cognitive decline and dementia: The Atherosclerosis Risk in Communities (ARIC) Study. Eur J Neurol 2011;18:888-98.

5. Barnes PJ. Chronic obstructive pulmonary disease: Effects beyond the lungs. PLoS Med 2010;7:E1000220.

6. Vasquez MM, Zhou M, Hu C, Martinez FD, Guerra S. Low lung function in young adult life is associated with early mortality. Am J Respir Crit Care Med 2017;195:1399-401.

7. Rennard SI, Drummond MB. Early chronic obstructive pulmonary disease: Definition, assessment, and prevention. Lancet 2015;385:1778-88.

8. Gordon SB, Bruce NG, Grigg J, Hibberd PL, Kurmi OP, Lam KB, *et al.* Respiratory risks from household air pollution in low and middle income countries. Lancet Respir Med 2014;2:823-60.

9. Postma DS, Bush A, van den Berge M. Risk factors and early origins of
chronic obstructive pulmonary disease. Lancet 2015;385:899-909.
10. Torres-Duque CA. Poverty cannot be inhaled and it is not a genetic condition. How can it be associated with chronic airflow obstruction? Eur Respir J 2017;49. pii: 1700823.
11. Brakema EA, van Gemert FA, van der Kleij RM, Salvi S, Puhan M, Chavannes NH. COPD’s early origins in low-and-middle income countries: What are the implications of a false start? NPJ Prim Care Respir Med 2019;29:6. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6401185/. [Last accessed on 2019 Jul 27].
12. Banda HT, Thomson R, Mortimer K, Bello GA, Mbera GB, Malmborg R, et al. Community prevalence of chronic respiratory symptoms in rural Malawi: Implications for policy. PLoS One 2017;12:e0188437. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5720679/. [Last accessed on 2019 Jul 27].
13. Meghji J, Nadeau G, Davis KJ, Wang D, Nyirenda MJ, Gordon SB, et al. Non communicable lung disease in sub-Saharan Africa. A community-based cross-sectional study of adults in Urban Malawi. Am J Respir Crit Care Med 2016;194:67-76.
14. Obaseki DO, Erhabor GE, Awopeju OF, Adewole OO, Adeniyi BO, Buist EA, et al. Reduced forced vital capacity in an African population. Prevalence and Risk Factors. Ann Am Thorac Soc 2017;14:714-21.
15. Cotes JE. Medical research council questionnaire on respiratory symptoms (1986). Lancet 1987;2:1028.
16. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J 2005;26:319-38.
17. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: The global lung function 2012 equations. Eur Respir J 2012;40:1324-43.
18. Quanjer PH, Prettio JJ, Brazzale DJ, Boros PW. Grading the severity of airways obstruction: New wine in new bottles. Eur Respir J 2014;43:505-12.
19. Polgar G, Weng TR. The functional development of the respiratory system from the period of gestation to adulthood. Am Rev Respir Dis 1979;120:625-95.
20. Fawibe AE, Adeigah LO, Saka MJ. Reference equations for spirometric indices from a sample of the general adult population in Nigeria. BMC Pulm Med 2017;17:48.
21. Braun L, Wolfgang M, Dickersin K. Defining race/ethnicity and explaining difference in research studies on lung function. Eur Respir J 2013;41:1362-70.
22. Duong M, Islam S, Rangarajan S, Teo K, O’Byrne PM, Schünemann HJ, et al. Global differences in lung function by region (PURE): An international, community-based prospective study. Lancet Respir Med 2013;1:599-609.
23. Cooper BG, Stocks J, Hall GL, Culver B, Steenbruggen I, Carter KW, et al. The Global Lung Function Initiative (GLI) Network: Bringing the world’s respiratory reference values together. Breathe (Sheff) 2017;13:e56-64.
24. Saad NJ, Patel J, Minelli C, Burney PGJ. Explaining ethnic disparities in lung function among young adults: A pilot investigation. PLoS One 2017;12:e0178962.
25. Burney P, Jithoo A, Kato B, Janson C, Mannino D, Nizankowska-Mogilnicka E, et al. Chronic obstructive pulmonary disease mortality and prevalence: The associations with smoking and poverty – A BOLD analysis. Thorax 2014;69:465-73.
26. Dania MG, Ozoh OB, Bandele EO. Smoking habits, awareness of risks, and attitude towards tobacco control policies among medical students in Lagos, Nigeria. Ann Afr Med 2015;14:1-7.
27. Ozoh OB, Aderibigbe SA, Ayuk AC, Desalu OO, Oridota OE, Olufemi O, et al. The prevalence of asthma and allergic rhinitis in Nigeria: A nationwide survey among children, adolescents and adults. PLoS One 2019;14:e0222281.
| Variable                                           | All participants \((n=640)\) | Participants with good quality spirometry \((n=464)\) | Participants without good quality spirometry \((n=176)\) | \(P\)  |
|----------------------------------------------------|-------------------------------|-------------------------------------------------------|-----------------------------------------------------|------|
| **Shortness of breath**                            |                               |                                                       |                                                     |      |
|Hurrying on level ground or slight hill             | 154 (24.1)                    | 115 (24.8)                                            | 39 (22.2)                                           | 0.49 |
|Walking with age mates                              | 28 (4.4)                      | 20 (4.3)                                              | 8 (4.5)                                             | 0.82 |
|Stop for breath at own pace                         | 11 (1.7)                      | 6 (1.3)                                               | 5 (2.8)                                             | 0.13 |
|**Exercise-induced symptoms**                       |                               |                                                       |                                                     |      |
|Cough                                               | 34 (5.3)                      | 24 (5.2)                                              | 10 (5.7)                                            | 0.80 |
|Wheeze                                              | 50 (7.8)                      | 37 (8.0)                                              | 13 (7.4)                                            | 0.80 |
|Chest tightness                                     | 120 (18.8)                    | 93 (20.0)                                             | 7 (15.3)                                            | 0.17 |
|All three symptoms                                  | 13 (2.0)                      | 8 (1.7)                                               | 5 (2.8)                                             | 0.12 |
|**Sleep-related symptoms**                          |                               |                                                       |                                                     |      |
|Sleep broken by wheeze                              | 27 (4.2)                      | 21 (4.5)                                              | 6 (3.4)                                             | 0.53 |
|Sleep broken by difficulty breathing                | 57 (8.9)                      | 41 (8.8)                                              | 16 (9.1)                                            | 0.92 |
|Woken by wheeze                                     | 27 (4.2)                      | 21 (4.5)                                              | 6 (3.4)                                             | 0.53 |
|Woken by difficulty breathing                       | 50 (7.8)                      | 33 (7.1)                                              | 17 (9.7)                                            | 0.28 |
|**Trigger-related symptoms**                        |                               |                                                       |                                                     |      |
|Wheeze in a smoky room                              | 117 (18.3)                    | 83 (17.9)                                             | 34 (19.3)                                           | 0.68 |
|Wheeze in a dusty place                             | 140 (21.9)                    | 100 (21.6)                                            | 40 (22.7)                                           | 0.75 |
|**Cough**                                           |                               |                                                       |                                                     |      |
|Morning cough during cold weather                   | 52 (8.1)                      | 37 (8.0)                                              | 15 (8.5)                                            | 0.82 |
|Day or night cough during cold weather              | 108 (16.9)                    | 79 (17.0)                                             | 29 (16.5)                                           | 0.38 |
|Cough on most days for 3 months/year                | 22 (3.4)                      | 17 (3.7)                                              | 5 (2.8)                                             | 0.61 |
|**Phlegm**                                          |                               |                                                       |                                                     |      |
|Morning phlegm during cold weather                  | 61 (9.5)                      | 46 (9.9)                                              | 15 (8.5)                                            | 0.59 |
|Day or night phlegm during cold weather             | 86 (13.4)                     | 61 (13.1)                                             | 25 (14.2)                                           | 0.73 |
|Phlegm on most days for 3 months/year               | 34 (5.3)                      | 24 (5.2)                                              | 10 (5.7)                                            | 0.80 |
|Any respiratory symptom                             | 337 (52.7)                    | 244 (52.6)                                            | 93 (52.8)                                           | 0.95 |
|**Number of domains with symptoms**                 |                               |                                                       |                                                     |      |
|1                                                   | 119 (18.6)                    | 18 (17.5)                                             | 38 (21.6)                                           | 0.59 |
|2                                                   | 88 (13.8)                     | 65 (14.0)                                             | 23 (13.1)                                           | 0.07 |
|3                                                   | 67 (10.5)                     | 47 (10.1)                                             | 20 (11.4)                                           | 0.14 |
|4                                                   | 35 (5.5)                      | 30 (6.5)                                              | 5 (2.8)                                             | 0.17 |
|5                                                   | 19 (3.0)                      | 14 (3.0)                                              | 2 (2.8)                                             |      |
|6                                                   | 9 (1.4)                       | 7 (1.5)                                               | 2 (1.1)                                             |      |
|Ever has bronchitis or COPD                         | 8 (1.3)                       | 8 (1.7)                                               | 0 (0.0)                                             | 0.08 |
|Ever had asthma                                     | 49 (7.7)                      | 39 (8.4)                                              | 10 (5.7)                                            | 0.25 |
|Ever had allergic rhinitis                          | 29 (4.5)                      | 17 (3.7)                                              | 12 (6.8)                                            | 0.09 |
|Previously treated for tuberculosis                 | 16 (2.5)                      | 10 (2.2)                                              | 6 (3.4)                                             | 0.36 |

COPD – Chronic obstructive pulmonary disease
| Age group | SOB | Exercise | Sleep | Trigger | Cough | Phlegm | Any respiratory symptom |
|-----------|-----|----------|-------|---------|-------|--------|-------------------------|
| Males     |     |          |       |         |       |        |                         |
| 16-19     | 8 (18.2) | 6 (13.6) | 3 (6.8) | 10 (22.7) | 6 (13.6) | 9 (20.5) | 19 (43.2) |
| 20-24     | 21 (15.8) | 23 (17.3) | 18 (13.5) | 33 (24.8) | 22 (16.5) | 17 (12.8) | 58 (43.6) |
| 25-29     | 3 (9.4) | 5 (15.6) | 4 (12.5) | 6 (18.8) | 2 (6.3) | 4 (12.5) | 10 (31.3) |
| 30-35     | 1 (11.1) | 1 (11.1) | 1 (11.1) | - | 1 (11.1) | 1 (11.1) | 3 (33.3) |
| Females   |     |          |       |         |       |        |                         |
| 16-19     | 29 (41.4) | 29 (41.4) | 12 (17.1) | 24 (34.3) | 22 (31.8) | 16 (22.9) | 53 (75.7) |
| 20-24     | 45 (28.8) | 54 (34.6) | 30 (19.2) | 36 (23.1) | 31 (19.9) | 26 (16.7) | 89 (57.1) |
| 25-29     | 8 (47.1) | 6 (35.3) | 1 (1.9) | 4 (23.5) | 4 (23.5) | 2 (11.8) | 12 (70.6) |
| 30-35     | - | - | - | - | - | - | - |

SOB – Shortness of breath